Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A New Approach to Repurposing: Ditch the Hypotheses

This article was originally published in Start Up

Executive Summary

By pulling together 35 publicly available gold-standard animal models, Melior Discovery has built a stable of what it calls privileged compounds. The repurposing company augments its VC funds with service deals and is aiming to progress its lead compound into Phase I studies in 2007.
Advertisement

Related Content

OsteoCorp Inc.
APT Pharmaceuticals Inc.
The Value of Drug Repositioning: Longer Patent Life
Synosis: the Financial Leverage of Translational Medicine
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
NitroMed's BiDil Pricing: Test for a Whole Class of New Companies
The Search for Defensible IP in Older Drugs
The Search for Defensible IP in Older Drugs
In-Licensing: Still a Difficult Model
In-Licensing: Still a Difficult Model

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC091197

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel